Canaccord Genuity Maintains Buy on Orthofix Medical, Lowers Price Target to $13
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $18 to $13.
Stocks · News reference
Orthofix Medical Raises FY2026 Sales Guidance from $838.000M-$848.000M to $845.000M-$855.000M vs $843.311M Est
Orthofix Medical (NASDAQ:OFIX) raises FY2026 sales outlook from $838.000 million-$848.000 million to $845.000 million-$855.000 million vs $843.311 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Orthofix shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
8-K filing — Orthofix Medical Inc. (OFIX)
Filed: 2026-08-05 AccNo: 0001193125-26-333817 Size: 30 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits